- Research works
- 66 ▼ 20% vs 2018-21
- Citations
- 1.1k 16.0 per fractional work
- Top-10% rate
- 21.1% all institutions 10.0%
- Open access
- 27% world 40%
- International
- 8% world 18%
Not ranked overall: Mersana Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does Mersana Therapeutics (United States) work in?
In all years, 68% of research at Mersana Therapeutics (United States) is in Health Sciences, 26% in Life Sciences. Its largest fields are Medicine (68%), Biochemistry, Genetics and Molecular Biology (19%), Immunology and Microbiology (7%). It does 2.6× the world's share of Health Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 3 domains and 12 fields, with their numbers
- Health Sciences4567.8%
- Medicine4567.6%
- Health Professions00.2%
- Veterinary00.1%
- Life Sciences1726.0%
- Physical Sciences46.2%
- Engineering12.2%
- Chemistry12.2%
- Computer Science11.0%
- Materials Science00.7%
- Environmental Science00.2%
- Physics and Astronomy00.0%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 13.9×. Every wedge is a field page.
All 11 fields, with their numbers
- Immunology and Microbiology13.89×3 works
- Biochemistry, Genetics and Molecular Biology3.86×4 works
- Chemistry3.30×1 works
- Medicine2.86×11 works
- Veterinary1.46×0 works
- Materials Science0.49×0 works
- Computer Science0.22×0 works
- Health Professions0.22×0 works
- Neuroscience0.18×0 works
- Environmental Science0.13×0 works
- Physics and Astronomy0.04×0 works
Who are the top researchers at Mersana Therapeutics (United States)?
Ranked on the quality score, Donald Alan Bergstrom, Marc Isaac Damelin and Timothy B. Lowinger lead among researchers whose main affiliation is Mersana Therapeutics (United States).
- 1
Donald Alan Bergstrom
United States · #205,677 worldwide 3.2k citations · 248 works
- 2
Marc Isaac Damelin
United States · #274,167 worldwide 2.8k citations · 195 works
- 3
Timothy B. Lowinger
United States · #300,214 worldwide 3.9k citations · 211 works
- 4
Raghida A. Bukhalid
United States · #314,766 worldwide 1.9k citations · 68 works
- 5
Rebecca E. Mosher
United States · #324,995 worldwide 2.4k citations · 123 works
- 6
Michael J. DeVit
United States · #325,583 worldwide 4.2k citations · 39 works
- 7
Laura L. Poling
United States · #460,852 worldwide 1.9k citations · 60 works
- 8
LiuLiang Qin
United States · #464,145 worldwide 2.3k citations · 152 works
- 9
Elena Ter‐Ovanesyan
United States · #470,054 worldwide 489 citations · 104 works
- 10
Chen‐Ni Chin
United States · #599,022 worldwide 2.1k citations · 38 works
Which keywords describe research at Mersana Therapeutics (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Breast Cancer and Metastatic.
- Chimeric Antigen Receptor
- Biomarkers
- Immunosuppression
- Angiogenesis
- Bacterial Therapy
- Clinical Trials
- Interferon Signaling
- Gene Therapy
- Innate Immunity
- Neurotoxicity
- Tumor Microenvironment
- Cancer Therapy
- Metastatic Breast Cancer
- Radioimmunotherapy
- PET Imaging
- Trastuzumab
- Metastatic
- Fc Receptors
- Therapeutic Antibodies
- Glycosylation
- Chemotherapy
- Monoclonal Antibodies
- Antibody Engineering
- Breast Cancer
- HER2
- Immunotherapy
- Targeted Therapy
- Radiopharmaceuticals
- Tumor Regression
- Quality of Life
- Chemotherapy-Induced Peripheral Neuropathy
- Taxanes
- Tumor Targeting
- Pattern Recognition Receptors
- Viral Infection
- Arginine Deprivation
- Cancer Immunotherapy
- Fibroblast Activation Protein
- Metastasis
- CAR T Cells
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy15▲ 32×7 topics
- Glycosylation12▲ 85×2 topics
- Monoclonal Antibodies12▲ 129×3 topics
- Therapeutic Antibodies12▲ 144×2 topics
- Antibody Engineering12▲ 178×1 topic
- Fc Receptors12▲ 178×1 topic
- Breast Cancer11▲ 58×3 topics
- Metastatic11▲ 252×2 topics
- HER210▲ 521×1 topic
- Trastuzumab10▲ 369×1 topic
- Immunotherapy8▲ 19×8 topics
- PET Imaging7▲ 47×2 topics
- Targeted Therapy6▲ 45×4 topics
- Radioimmunotherapy4▲ 168×1 topic
- Radiopharmaceuticals4▲ 168×1 topic
- Metastatic Breast Cancer4▲ 99×2 topics
- Tumor Regression4▲ 74×2 topics
- Cancer Therapy4▲ 10×6 topics
- Quality of Life4▲ 4.8×3 topics
- Tumor Microenvironment4▲ 18×7 topics
- Chemotherapy-Induced Peripheral Neuropathy4▲ 123×1 topic
- Neurotoxicity4▲ 34×2 topics
- Taxanes4▲ 123×1 topic
- Innate Immunity4▲ 17×3 topics
- Tumor Targeting4▲ 45×3 topics
- Gene Therapy4▲ 21×3 topics
- Pattern Recognition Receptors4▲ 37×2 topics
- Interferon Signaling3▲ 151×1 topic
- Viral Infection3▲ 67×1 topic
- Clinical Trials3▲ 7.0×4 topics
- Arginine Deprivation2▲ 86×1 topic
- Bacterial Therapy2▲ 86×1 topic
- Cancer Immunotherapy2▲ 26×2 topics
- Angiogenesis2▲ 8.5×2 topics
- Fibroblast Activation Protein2▲ 67×1 topic
- Immunosuppression2▲ 30×1 topic
- Metastasis2▲ 10×4 topics
- Biomarkers2▲ 5.4×2 topics
- CAR T Cells2▲ 61×1 topic
- Chimeric Antigen Receptor2▲ 61×1 topic
Which research topics does Mersana Therapeutics (United States) publish most on?
By volume in 2022-now: Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, interferon and immune responses and Peptidase Inhibition and Analysis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 2 HER2/EGFR in Cancer Research Oncology 2 works
- 3 interferon and immune responses Immunology 2 works
- 4 Peptidase Inhibition and Analysis Oncology 1 works
- 5 Cancer Research and Treatments Biotechnology 1 works
- 6 Ovarian cancer diagnosis and treatment Reproductive Medicine 1 works
- 7 Neuroblastoma Research and Treatments Neurology 1 works
- 8 Virus-based gene therapy research Genetics 1 works
- 9 Cancer Treatment and Pharmacology Oncology 0 works
- 10 Lung Cancer Research Studies Oncology 0 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has Mersana Therapeutics (United States)'s research output changed?
Output in 2022-2025 was 20% lower than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Mersana Therapeutics (United States) as a percentage of every work published that year, 0.000090% in 2024.
Fractional works of Mersana Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Cambridge
- Harvard University
- Massachusetts Institute of Technology
- National Bureau of Economic Research
- World Wide Web Consortium
- Biogen (United States)
- Draper Laboratory
- Cambridge Health Alliance
- Harvard Global Health Institute
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Mersana Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.